Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases Part 2

Current Vascular Pharmacology
Antonis S Manolis, Athanasios G Tzioufas

Abstract

In Part 1 of this Thematic Issue entitled "Systemic Autoimmune Rheumatic Diseases and Cardiology", a panel of specialists and experts in cardiology, rheumatology, immunology and related fields discussed the cardiovascular complications of spondyloarthritides, rheumatoid arthritis, Sjogren's syndrome and vasculitides, as well as relevant cardiovascular issues related to non-biologic and biologic disease-modifying anti-rheumatic drugs (DMARDs), and provided their recommendations for prevention and management of these complications. In part 2 of this Thematic Issue, experts discuss the enhanced cardiovascular risk conferred by additional autoimmune rheumatic diseases (ARDs), including systemic lupus erythematosus, the antiphospholipid syndrome, psoriasis and psoriatic arthritis and juvenile idiopathic arthritis. These, and the previous articles, place inflammation as the key common link to explain the enhanced risk of cardiovascular complications in patients with ARDs. It follows that treatment should probably target inflammation. From all these contemporary reviews, the conclusion that is derived further supports the notion of the emerging field of CardioRheumatology where physicians and experts from these two disciplines collabo...Continue Reading

References

Feb 24, 2010·Clinical Science·Kim Van der HeidenPaul C Evans
Jun 7, 2011·Arthritis Research & Therapy·Geert van Loo, Rudi Beyaert
Dec 24, 2014·Nature Reviews. Cardiology·Megha PrasadAmir Lerman
Feb 28, 2015·Current Atherosclerosis Reports·Rekha Mankad
Feb 9, 2016·Scandinavian Journal of Rheumatology·J H AndersonB Flatø
Jul 16, 2016·Rheumatology International·Bulent KocaOzgur Kasapcopur
Aug 25, 2017·Nature Reviews. Cardiology·Elena BartoloniRoberto Gerli
Jan 26, 2018·Hellenic Journal of Cardiology : HJC = Hellēnikē Kardiologikē Epitheōrēsē·Ntobeko A B NtusiTheodoros D Karamitsos
Mar 3, 2018·Frontiers in Medicine·Fabiola AtzeniMaurizio Turiel
Apr 25, 2018·BMJ : British Medical Journal·Bryant R EnglandTed R Mikuls
Jun 21, 2018·Open Access Rheumatology : Research and Reviews·Sangeeta Sule, Kevin Fontaine
Nov 21, 2018·International Reviews of Immunology·Antonis A ManolisAntonis S Manolis
Dec 31, 2018·Pediatric Rheumatology Online Journal·Hanne Aaserud AulieSvend Aakhus
Feb 5, 2019·British Journal of Pharmacology·Erin B TaylorMichael J Ryan
May 31, 2019·Current Opinion in Lipidology·Rachel H MackeyLarry W Moreland
Jul 2, 2019·Current Vascular Pharmacology·George E FragoulisElena Nikiphorou
Jul 3, 2019·Trends in Cardiovascular Medicine·Antonis A ManolisAntonis S Manolis
Jul 25, 2019·Current Vascular Pharmacology·Charalampos PapagorasAlexandros A Drosos
Sep 19, 2019·Current Vascular Pharmacology·Kali PolytarchouAntonis S Manolis
Oct 1, 2019·Current Vascular Pharmacology·Iordanis S MourouzisConstantinos Pantos
Dec 28, 2019·Current Vascular Pharmacology·Myrto KostopoulouGeorge Bertsias
Jan 28, 2020·Current Vascular Pharmacology·Fabiola AtzeniPiercarlo Sarzi-Puttini
Jan 30, 2020·Current Vascular Pharmacology·Konstantinos MelissaropoulosDimitrios Daoussis
Feb 1, 2020·Current Vascular Pharmacology·Stergios SoulaidopoulosTheodoros Dimitroulas
Feb 15, 2020·Current Vascular Pharmacology·Maria DrakopoulouKonstantinos Toutouzas
Apr 10, 2020·Current Vascular Pharmacology·Elisavet ArsenakiGeorgios Georgiopoulos

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.